Oruka Therapeutics has had a sharp run over the past year, yet the recent pullback puts a spotlight on a different question for investors. Is the current share price still in line with what the company's book value can reasonably support?

• Over the past 12 months, Oruka Therapeutics has returned 171.0%, which puts a lot of pressure on today's valuation to be backed by something sturdier than momentum.

• The business model and balance sheet now matter more because book value, not just the share chart, needs to carry a larger share of the investment case.

• Your read on Oruka Therapeutics is one view; the desks covering it have another. See what analysts think Oruka Therapeutics's shares could be worth .

The stock's next move may depend on whether Oruka Therapeutics' current market value still lines up with what its book value suggests is reasonable.

If you are weighing whether Oruka Therapeutics' share price still lines up with its book value, it can help to compare that question across 35 high quality undervalued stocks .

Has Oruka Therapeutics Run Too Far on Book Value?

P/B is usually the cleaner yardstick for a pre-revenue biotech like Oruka Therapeutics because earnings and sales do not yet give a firm anchor. The stock trades around 4.4x P/B, which means the market is valuing the equity at more than four times its reported net assets.

The broader biotech group sits closer to 1.8x P/B, so Oruka Therapeutics carries a sizeable premium to the sector norm. That gap suggests investors are paying up for its pipeline and prospects relative to the cash and other assets on the balance sheet, which points to an overvalued reading on this single metric. Anyone considering the shares still needs to decide whether the research portfolio, team and funding runway justify paying that kind of mark up to book value. Explore the numbers behind Oruka Therapeutics's P/B valuation .

The Oruka Therapeutics Narrative: What Would Justify Today's Price?

Narratives for Oruka Therapeutics pick up where the book value puzzle leaves off, by spelling out which future paths for growth, profitability and earnings would need to play out for the stock to be worth meaningfully more or less than today's valuation. Instead of stopping at a single P/B figure, they unpack the business assumptions beneath it so you can watch how Oruka Therapeutics' real world progress lines up with the story implied by that number.

A clear, number-driven Narrative on Oruka Therapeutics helps turn a loose story about promise into a concrete set of assumptions that can be checked against future funding, trial progress and cash burn. Putting those expectations on paper now gives you a reference point to revisit as new data arrives and the share price, sentiment and balance sheet move around those initial views.